Related Experiment Video

Updated: May 16, 2026

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Leveraging fluorinated glucosamine action to boost antitumor immunity

Charles J Dimitroff1

  • 1Department of Dermatology, Brigham and Women's Hospital, Boston, MA 02115, United States. cdimitroff@rics.bwh.harvard.edu

Current Opinion in Immunology
|December 11, 2012
PubMed

Insights

Fluorinated glucosamines can reduce N-acetyllactosamines on antitumor T cells, diminishing galectin-1 binding. This approach enhances T cell function and boosts antitumor immunity.

Area of Science:

  • Immunology
  • Glycobiology
  • Cancer Biology

Background:

  • N-acetyllactosaminyl glycans regulate T cell antitumor activity.
  • Galectin-1 (Gal-1) binding to these glycans can induce T cell apoptosis or immune suppression.
  • Tumor-derived Gal-1 protects cancer cells from T cell-mediated destruction.

Purpose of the Study:

  • To explore the potential of fluorinated glucosamines in cancer immunotherapy.
  • To investigate methods for antagonizing N-acetyllactosamine expression or function.
  • To enhance T cell-mediated antitumor responses.

Main Methods:

  • Utilizing fluorinated glucosamines to target N-acetyllactosamines on T cells.
  • Assessing the impact of these compounds on galectin-1 binding.
  • Evaluating changes in antitumor T cell levels and function.

Main Results:

  • Fluorinated glucosamines effectively reduce N-acetyllactosamine expression.
  • Diminished galectin-1 binding to T cells was observed.
  • Increased levels and improved effector function of antitumor T cells were noted.

Conclusions:

  • Fluorinated glucosamines show promise for cancer immunotherapy by modulating T cell glycosylation.
  • Targeting N-acetyllactosamines offers a strategy to overcome tumor-induced immune suppression.
  • This approach could lead to enhanced T cell-mediated antitumor immunity.

More Related Videos

Isolation and Purification of Fungal β-Glucan as an Immunotherapy Strategy for Glioblastoma10:02

Isolation and Purification of Fungal β-Glucan as an Immunotherapy Strategy for Glioblastoma

Published on: June 2, 2023

Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment10:33

Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment

Published on: April 25, 2025

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...